Response to one infusion predicts subsequent improvement as well as the rate of relapse of ankylosing spondylitis infused with three pulses of infliximab

Clinical Rheumatology

Volumn 26, Issue 6, 2007, Pages 920-926

  Huang, Feng ^a   Zhu, Jian ^a   Zhang, Liyun ^a   Zhang, Jianglin ^a   Zhang, Fengchun ^b   Yu, David ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ankylosing spondylitis; Infliximab; Relapse and improvement predictor

Indexed keywords

INFLIXIMAB; PREDNISONE;

ADULT; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PULSE THERAPY, DRUG; RECURRENCE; ROC CURVE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34250774611     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0434-8     Document Type: Article

References (14)

1. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667-1675
2. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359:1187-1193
3. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582-591
4. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E et al (2002) Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-label study. Rheumatology (Oxford) 41:1280-1285
5. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439-R444
6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-2291
7. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
8. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-2285
9. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J Rheumatol 21:1694-1698
10. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC (1987) Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 46:197-202
11. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876-1886
12. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63:665-670
13. Davis JC Jr, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO et al (2005) Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 32:1751-1754
14. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817-824